Publications by authors named "Hilal Ahmed Parray"

Article Synopsis
  • * Binding studies indicate that II62 effectively interacts with various SARS-CoV-2 variants without disrupting the virus's ability to bind to the ACE2 receptor.
  • * Neutralization tests show that increasing the antibody's valency from monovalent to tetravalent does not negatively affect its interaction with host cells in virus testing assays.
View Article and Find Full Text PDF

Cross-reactivity among the two diverse viruses is believed to originate from the concept of antibodies recognizing similar epitopes on the two viral surfaces. Cross-reactive antibody responses have been seen in previous variants of SARS and SARS-CoV-2, but little is known about the cross reactivity with other similar RNA viruses like HIV-1. In the present study, we examined the reactivity the SARS-CoV-2 directed antibodies, via spike, immunized mice sera and demonstrated whether they conferred any cross-reactive neutralization against HIV-1.

View Article and Find Full Text PDF
Article Synopsis
  • Advancements in technology have led to the development of numerous new antibody-based therapies, with over 700 molecules currently in various clinical trial phases and more than 80 monoclonal antibodies approved for use.
  • In 2019 alone, 7 novel antibody therapeutics were approved, making up 20% of all newly approved drugs in the U.S. and EU.
  • The review discusses hybridoma technology, its evolution across different species, its benefits for isolating antibodies, and the challenges faced in development, highlighting recent progress in the field.
View Article and Find Full Text PDF

Monoclonal antibodies (mAbs) and their derivatives have achieved remarkable success as medicine, targeting both diagnostic and therapeutic applications associated with communicable and non-communicable diseases. In the last 3 to 4 decades, tremendous success has been manifested in the field of cancer therapy, autoimmune diseases, cardiovascular and infectious diseases. MAbs are the fastest growing class of biopharmaceuticals, with more than 25 derivatives are in clinical use and 7 of these have been isolated through phage display technology.

View Article and Find Full Text PDF